𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis

✍ Scribed by Hans Carl Hasselbalch; Ole Weiss Bjerrum; Bjarne Anker Jensen; Nielsaage Tøffner Clausen; Per Boye Hansen; Henrik Birgens; Marianne Hamilton Therkildsen; Elisabeth Ralfkiær

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
68 KB
Volume
74
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate in chordoma
Imatinib mesylate in chordoma
✍ Paolo G. Casali; Antonella Messina; Silvia Stacchiotti; Elena Tamborini; Flavio 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 716 KB
Significance of myelofibrosis in early c
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
✍ Hagop M. Kantarjian; Carlos E. Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. ## METHODS The current study evaluated the significance of the

Idiopathic myelofibrosis terminating in
Idiopathic myelofibrosis terminating in erythroleukemia
✍ Dr. Sonia Garcia; Amparo Miguel; Alicia Miguel; Mariano Linares; Miguel Navarro; 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB

A 55-year-old woman with a one-year history of idiopathic myelofibrosis progressed to erythroleukemia. This is the first reported occurrence of erythroleukemia progression from idiopathic myelofibrosis. Certain patterns of leukemia transformation from myeloproliferative disorders are favored: Myelob

Imatinib mesylate causes hypopigmentatio
Imatinib mesylate causes hypopigmentation in the skin
✍ Anne S. Tsao; Hagop Kantarjian; Jorge Cortes; Susan O'Brien; Moshe Talpaz 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

## Background: Imatinib mesylate is a tyrosine kinase inhibitor that targets the bcr-abl protein in cml, c-kit (kit) and platelet-derived growth factor receptors. in clinical trials with imatinib mesylate, common side effects of nausea, emesis, diarrhea, periorbital edema, fluid retention, and myel

Imatinib mesylate causes hypopigmentatio
Imatinib mesylate causes hypopigmentation in the skin
✍ Kin Wah Leong; Thoong Chow Lee; Ai Sim Goh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

## Cancer-Related Fatigue: Evolving Concepts in Evaluation and Treatment I n their otherwise excellent review of cancer-related fatigue, Stasi et al. 1 failed to discuss opioid-induced androgen deficiency (OPIAD), an extremely common and easily identified cause of fatigue in men with malignant dis